The next-generation Open Targets Platform: reimagined, redesigned, rebuilt

Area of Science:

• Genomics
• Pharmacology
• Bioinformatics

Background:

• The Open Targets Platform is a key open-source resource for drug target identification and prioritization.
• Previous versions facilitated systematic analysis of publicly available data.

Purpose of the Study:

• To systematically update and enhance the Open Targets Platform for improved drug target identification and prioritization.
• To streamline data integration, expand data exploration, and enhance user experience.

Main Methods:

• Reimagined, redesigned, and rebuilt the Platform architecture.
• Enhanced gene-disease causal evidence for rare, common, and somatic diseases.
• Incorporated new features for target safety (genetic constraint) and tractability (PROTACtability, AlphaFold structures).
• Introduced machine learning for knowledge extraction from literature, clinical trials, and drug labels.

Main Results:

• Streamlined data integration and harmonization processes.
• Expanded gene-disease causal evidence, improving disease causality assessment.
• Added novel features for target safety and tractability analysis.
• Implemented machine learning for enhanced knowledge extraction.
• Introduced new technologies for easier feature integration and platform customization.

Conclusions:

• The redesigned Open Targets Platform offers a more robust and user-friendly resource for drug discovery.
• Enhanced data, new features, and improved infrastructure support systematic target identification and prioritization.
• New machine learning applications and community support further empower researchers in diverse use cases.